Idiopathic pulmonary fibrosis: treatment update.

Hdl Handle:
http://hdl.handle.net/10147/218049
Title:
Idiopathic pulmonary fibrosis: treatment update.
Authors:
O'Connell, Oisin J; Kennedy, Marcus P; Henry, Michael T
Affiliation:
Department of Respiratory Medicine, Cork University Hospital, Wilton, Cork, Ireland.
Citation:
Idiopathic pulmonary fibrosis: treatment update. 2011, 28 (11):986-99 Adv Ther
Journal:
Advances in therapy
Issue Date:
Nov-2011
URI:
http://hdl.handle.net/10147/218049
DOI:
10.1007/s12325-011-0066-5
PubMed ID:
21975927
Abstract:
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.
Language:
en
MeSH:
Anti-Inflammatory Agents; Anticoagulants; Antioxidants; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Lung Transplantation; Medication Therapy Management; Outcome Assessment (Health Care); Oxygen Inhalation Therapy; Palliative Care; Receptors, Endothelin; Tumor Necrosis Factor-alpha
ISSN:
1865-8652
Ethical Approval:
N/A

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Connell, Oisin J-
dc.contributor.authorKennedy, Marcus P-
dc.contributor.authorHenry, Michael T-
dc.date.accessioned2012-04-10T13:15:16Z-
dc.date.available2012-04-10T13:15:16Z-
dc.date.issued2011-11-
dc.identifier.citationIdiopathic pulmonary fibrosis: treatment update. 2011, 28 (11):986-99 Adv Ther-
dc.identifier.issn1865-8652-
dc.identifier.pmid21975927-
dc.identifier.doi10.1007/s12325-011-0066-5-
dc.identifier.urihttp://hdl.handle.net/10147/218049-
dc.description.abstractIdiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.-
dc.language.isoen-
dc.rightsArchived with thanks to Advances in therapyen_GB
dc.subject.meshAnti-Inflammatory Agents-
dc.subject.meshAnticoagulants-
dc.subject.meshAntioxidants-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshDisease Progression-
dc.subject.meshHumans-
dc.subject.meshIdiopathic Pulmonary Fibrosis-
dc.subject.meshImmunosuppressive Agents-
dc.subject.meshLung Transplantation-
dc.subject.meshMedication Therapy Management-
dc.subject.meshOutcome Assessment (Health Care)-
dc.subject.meshOxygen Inhalation Therapy-
dc.subject.meshPalliative Care-
dc.subject.meshReceptors, Endothelin-
dc.subject.meshTumor Necrosis Factor-alpha-
dc.titleIdiopathic pulmonary fibrosis: treatment update.en_GB
dc.contributor.departmentDepartment of Respiratory Medicine, Cork University Hospital, Wilton, Cork, Ireland.-
dc.identifier.journalAdvances in therapy-
dc.type.qualificationlevelN/Aen
cr.approval.ethicalN/Aen
dc.description.provinceMunsteren
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.